Skip to main content

Table 2 Baseline values for outcome variables for diabetes, hypertension and dyslipidemia guidelines in the control and intervention groups

From: Results from the CLUES study: a cluster randomized trial for the evaluation of cardiovascular guideline implementation in primary care in Spain

  Control group (% of patients) Intervention group (% of patients)
Diabetes guideline
 Annual HbA1c testing 77.05 76.18
 HbA1c < 7% 44.53 44.94
 Annual general laboratory testing 42.13 38.18
 Annual coronary risk assessment 10.48 10.88
 Annual foot examination 44.87 40.12
 Blood pressure < 140/80 mmHg 21.22 21.47
 Metformin/All new antidiabetic monotherapy 85.61 85.55
Hypertension guideline
 Annual basic lab examination 24.46 21.81
 Blood pressure < 140/90 mmHg 29.98 31.47
 Annual coronary risk assessment 10.77 11.46
 Diuretics/All new antihypertensive monotherapy 11.41 10.57
 Beta blockers/All new antihypertensive monotherapy 6.85 7.77
 ARB-II/All new antihypertensive monotherapy 28.75 26.23
Dyslipidemia guideline
 Women with coronary risk assessment 7.73 7.48
 Men with coronary risk assessment 7.70 7.06
 New statin treatments with previous coronary risk assessment 10.60 10.17
 New statin treatments in low-risk women 3.21 3.25
 Patients with coronary heart disease receiving statin treatment 76.54 73.56
  1. ARB-II angiotensin II receptor blocker